hpv16 e7

This is amino acids 86 to 93 fragment of the human papilloma virus (HPV) type 16 oncoprotein E7. This HPV16-encoded peptide has very high affinity of binding to the HLA-A*0201 molecule.This immunogenic fragment may be used in vaccines for the prevention a

HPV16 E7 (86-93) acetate is a derived peptide of human leukocyte antigen A2.1 restricted HPV16 E7 with immunogenic property in cervical carcinomas.

HPV16 E7 (86-93) TFA, a peptide derived from HPV16 E7, is restricted by human leukocyte antigen (HLA)-A2.1 and exhibits immunogenic properties in cervical carcinomas [1] [2].

HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide.

HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein, demonstrating high-affinity binding to HLA-A2 in vitro.

DSPE-PEG(2000)-mannose, a pegylated and mannosylated derivative of 1,2-DSPE, has been employed in both in vitro and in vivo studies for delivering peptides, oligodeoxynucleotides, and siRNA via liposomes and lipid nanoparticles (LNPs). Fluorescently labeled LNPs containing DSPE-PEG(2000)-mannose predominantly accumulate in the liver and spleen of mice, significantly more so than in the brain, lungs, heart, kidneys, and pancreas. In immunization studies, liposomes encapsulating Human Papillomavirus type 16 (HPV16) E7 peptides with CpG oligodeoxynucleotides as an adjuvant led to reduced tumor volume and decreased numbers of CD4+ or CD8+ T cells and angiogenesis within tumors in a mouse lung cancer model using TC-1 cells.

Verpasep caltespen (HspE7), a recombinant fusion protein, originates from the Mycobacterium bovis Calmette-Guérin heat shock protein 65 (Hsp65) and is covalently bonded at its C-terminal end to the E7 protein of HPV16. This compound has applications in researching both precancerous and cancerous lesions linked to the human papillomavirus (HPV) [1] [2].